Table of Contents

The molecular pathogenesis and pathophysiology of prostate cancer
    William G. Nelson, Angelo M. De Marzoo

Targeted therapies for cancer: definitions and attributes
    Edward A. Sausville

Novel biomarkers for disease diagnosis, prognosis, and prediction
    James V. Tricoli

The endothelin pathway and its modulation in prostate cancer
    Antonio Jimeno, Michael Carducci

Targeting extracellular molecules in prostate cancer - mechanisms to inhibit entry into the cell-signaling abyss
    Susan F. Slovin

Immunologic approaches to prostate cancer
    Lawrence Fong, Eric J. Small

Gene therapy and novel clinical trial design
    Henry T. Tsai, Jonathan W. Simons

Angiogenesis inhibitors in prostate cancer
    William D. Figg, Michael C. Cox, Tania Alachalabi, William L. Dahut

What antisense oligonucleotides have promise in prostate cancer
    Kim N. Chi, Martin E. Gleave

Novel approaches to androgen receptor blockade
    Ingo K. Mellinghoff

Can post-transcription modifiers change the course of prostate cancer?
    David Z. Qian, Roberto Pili

Telomere targeting agents
    Angelika M. Burger, Lloyd R. Kelland

Expanding the role of EGFR inhibitors in prostate cancer
    Srikala S. Sridhar, Malcolm J. Moore

Bone-directed therapy in prostate cancer: rationale and novel approaches
    Colby L. Eaton, Kate D. Linton, Freddie C. Hamdy

Inhibiting the proteasome in advanced prostate cancer
    Robert Dreicer

Hsp90: a target for prostate cancer therapy
    David B. Solit, Howard I. Scher, Neal Rosen

Vitamin D analogs and their role in prostate cancer
    Tomasz M. Beer, Anne Myrthue

Other novel therapies
    Arif Hussain, Richard Schraeder

Molecular imaging, clinical trial design, and the development of emerging therapies for metastatic prostate cancer
    Michael J. Morris, Neeta Pandit-Taksar, Chaitanya Divgi, Steven Larson, Howard I. Scher